Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
Beijing Children's Hospital
New York Medical College
National Institutes of Health Clinical Center (CC)
Milton S. Hershey Medical Center
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center